Glial cell line-derived neurotrophic factor

• US 6,093,802 A
• Filed: 05/26/1995
• Issued: 07/25/2000
• Est. Priority Date: 09/20/1991
• Status: Expired due to Term

• Current Assignee: Amgen Inc.
• Original Assignee: Amgen Inc.
• Inventors: Doherty, Daniel H., Lin, Leu-Fen H., Lile, Jack, Collins, Franklin D., Bektesh, Susan
• Primary Examiner(s): Schain, Howard E.
• Application Number:
  US08/451,374
• Time in Patent Office: 1,887 Days
• Field of Search: 530/399, 530/417, 530/413, 530/416, 435/68.1, 435/70.1, 435/70.3, 435/70.4, 435/71.1, 435/71.2
• US Class Current: 530/399
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 9/0085 Brain, e.g. brain implants; Spinal cord
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/26 Psychostimulants, e.g. nicotine, cocaine
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: C07K 14/475 Growth factors; Growth regulators
• CPC Class Codes: Y10S 530/809 Fused cells, e.g. hybridoma
• CPC Class Codes: Y10S 530/839 Nerves; brain

Abstract

A novel neurotrophic factor referred to as glial cell line-derived neurotrophic factor (GDNF) has been identified and isolated from serum free growth conditioned medium of B49 glioblastoma cells. Rat and human genes encoding GDNF have been cloned and sequenced. A gene encoding GDNF has been subcloned into a vector, and the vector has been used to transform a host cell in order to produce biologically active GDNF in a recombinant DNA process.

Claims

1. A method for obtaining substantially purified glial cell line-derived neurotrophic factor protein, comprising:

culturing cells which are transformed to express a neurotrophic factor protein selected from the group consisting of;

(a)

space="preserve" listing-type="tabular">Ser Pro Asp Lys Gln Met Ala Val Leu Pro Arg Arg Glu - Arg Asn Arg Gln Ala Ala Ala Ala Asn Pro Glu Asn Ser - Arg Gly Lys Gly Arg Arg Gly Gln Arg Gly Lys Asn Arg - Gly Cys Val Leu Thr Ala Ile His Leu Asn Val Thr Asp - Leu Gly Leu Gly Tyr Glu Thr Lys Glu Glu Leu Ile Phe - Arg Tyr Cys Ser Gly Ser Cys Asp Ala Ala Glu Thr Thr - Tyr Asp Lys Ile Leu Lys Asn Leu Ser Arg Asn Arg Arg - Leu Val Ser Asp Lys Val Gly Gln Ala Cys Cys Arg Pro - Ile Ala Phe Asp Asp Asp Leu Ser Phe Leu Asp Asp Asn - Leu Val Tyr His Ile Leu Arg Lys His Ser Ala Lys Arg - Cys Gly Cys Ile of SEQ ID NO;

6; and

(b) a neurotrophic factor protein having at least the following properties of SEQ ID NO;

6

(i) a specific activity of at least about 12,000 TU/ug;

(ii) a molecular weight on reducing SDS-PAGE of about 20-23 kD;

(iii) a molecular weight on non-reducing SDS-PAGE of about 31-42 kD; and

(iv) a specific activity of at least about 24,000 times greater than the specific activity of B49-conditioned medium; and

isolating the neurotrophic factor protein.

2. The method of claim 1, further comprising:

lysing said cells to recover said neurotrophic factor protein; and

refolding said neurotrophic factor protein to provide a disulfide-bonded dimer.

3. The method of claim 1, wherein amino acid sequence further comprises an amino-terminal methionine residue.

4. The method of claim 1, for obtaining a substantially purified glial cell-line derived neurotrophic factor protein where in (b) the neurotrophic factor protein has the additional property (v) of being cross-reactive with an antibody to the neurotrophic factor protein of SEQ ID NO:

4 or SEQ ID NO;

6.

5. A method for obtaining a substantially purified glial cell line-derived neurotrophic factor protein, comprising the steps of:

(a) culturing cells which are transformed to express a neurotrophic factor protein, comprising an amino acid sequence of SEQ ID NO;

6; and

(b) isolating the neurotrophic factor protein.

6. The method of claim 5, wherein said neurotrophic factor protein is isolated by ion-exchange chromatography.

7. A method of claim 5, wherein said cells are bacterial cells.

8. The method of claim 7, wherein said cells are E. Coli cells.

9. The method of claim 8, wherein said neurotrophic factor protein further comprises an amino-terminal methionine residue.

10. The method of claim 9, further comprising the steps of:

(a) harvesting said cells;

(b) lysing said cells to recover said neurotrophic factor protein; and

(c) refolding said protein to provide a disulfide-bonded dimer. an amino-terminal methionine residue.

11. The method of claim 7, further comprising:

lysing said cells to recover said expressed protein; and

refolding said protein to provide a disulfide-bonded dimer.